Adam S. Kibel, MD, presented “Management of High Risk Prostate Cancer” during the 44th Annual Ralph E. Hopkins Urology Seminar on February 7, 2025, in Jackson Hole, Wyoming.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Kibel, Adam S. “Management of High Risk Prostate Cancer.” February 7, 2025. Accessed Apr 2025. https://grandroundsinurology.com/management-of-high-risk-prostate-cancer/
Management of High Risk Prostate Cancer – Summary
Adam S. Kibel, MD, presents on high-risk prostate cancer management. In this 20-minute presentation, Dr. Kibel emphasizes the importance of optimal staging, recognizing disease heterogeneity, and balancing treatment burden with effectiveness. Imaging, particularly PET scans, has significantly altered disease assessment, though sensitivity, particularly in identifying positive lymph nodes, remains a challenge.
Dr. Kibel contrasts treatment modalities, with evidence supporting the combination of radiation therapy and hormone therapy over monotherapy in terms of survival benefit. He shares that trials, such as the Swedish radical prostatectomy study, underscore the long-term survival advantage of surgery, particularly for high-risk patients. However, he acknowledges the limitations of retrospective comparisons between surgery and radiation.
Emerging strategies focus on integrating systemic therapies into localized treatment. Trials like STAMPEDE and PROTEUS explore intensified therapies such as abiraterone and enzalutamide, showing promising results in prolonging survival. Dr. Kibel concludes that the future of high-risk prostate cancer treatment likely involves a multimodal approach, combining local and systemic therapies to optimize disease control and survival outcomes.
About The 44th Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, sexual function, emerging surgical techniques, and general urology. The 44th iteration of the meeting took place from February 5th to February 8th, 2025, in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Adam S. Kibel, MD, is the DiNovi Family Distinguished Chair of Urology at Brigham and Women’s Hospital and Dana-Farber Brigham and Women’s Cancer Center in Boston, Massachusetts. Dr. Kibel is also the Elliott Carr Cutler Professor of Surgery at Harvard Medical School, and Chairman of the Harvard Urology Residency Program. His clinical interests include genetics of prostate cancer, minimally-invasive surgical treatments for urologic cancers, and robotic surgery for urologic cancers.
Dr. Kibel received his undergraduate and medical degrees from Cornell University Medical School. Dr. Kibel completed his urology residency at the Harvard Urology Program and his fellowship at the Brady Urologic Institute at John Hopkins.
Dr. Kibel has been listed as one of America’s Top Doctors by Castle Connolly and was named a top urologist by Boston magazine for his work on minimally invasive treatments for urologic cancers. Dr. Kibel has authored over 250 peer-reviewed publications on his research, with topics including the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease and improved imaging of patients with urologic malignancies. Dr. Kibel’s research has been supported by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.
